



SUVEN Life Sciences

Communication to investors **September 2014**

14-Nov-14

2014-15 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

		Q2 Sep 14	HY Sep 14
Growth in revenue		-6.83%	7.79%
Growth in PAT		-45.48%	-20.90%
Growth in EBIDTA		-44.35%	-16.09%
Growth in Pre-R&D EBIDTA		-43.21%	-17.31%
Increase in R&D Costs		-38.67%	-22.84%
R&D to sales		7.78%	7.02%


MAJOR PROFITABILITY RATIOS



	Q2 Sep 14	HY Sep 14
PAT to Income	17.59%	20.99%
EBIDTA to Income	28.19%	34.80%
Cash Flow to Income	21.63%	25.27%
Pre-R&D EBITDA to Income	35.97%	41.82%



INCOME COMPARISON




14-Nov-14

2014-15 Q2 results




PROFIT COMPARISON





EBIDTA COMPARISON




14-Nov-14

2014-15 Q2 results




R & D – EXPENDITURE





PRE-R&D EBIDTA




14-Nov-14

2014-15 Q2 results



PRE-R&D CASHFLOW





News releases

- Suven has **678** product patents for **18** inventions and **35** process patents
- Number of active CRAMS projects during period - **99**
- SUVN 502 completed Phase **1b** clinical trial in USA and preparation for entering Phase **2a** clinical trial has commenced
- SUVN-G3031 for Cognition in Alzheimer's Disease commenced Phase **1** Clinical Trial in USA under US-IND 123179
- Suven is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014.
- Suven bags Pharmexcil's "Gold Patent Award" for NCE's and "Outstanding Export Performance Award" for Contract Research and Manufacturing.



News releases

- PAT for the quarter was reduced by Rs. 32.2 Mn, & for the Half year reduced by Rs.72.8 Mn due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. Had the similar provisions of same quarter of previous years would have been followed been, the PAT for this quarter would have been higher by Rs. 32.2 Mn. & as well as Rs.72.8 Mil for the half year ended 30/sept/2014.
- Lower revenue and PAT during this quarter compared to the same quarter last year is due to the absence of pre-launch supplies of intermediates for 3 of the NCE's which were done last year. The repeat order for these supplies may happen after a gap of 12-18 months since the last supplies.



Patent news release

- One (1) product patent from Eurasia (019496), One (1) product patent from Australia (2010337836), One (1) product patent from USA (8735423), one (1) product patent from South Korea (10-1410903), One (1) product patent from South Korea (10-1386354), one (1) product patent from China (CN102639526) and one (1) product patent from Canada (CA 2737282) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 to 2031.